🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou, Shantou, Ganzhou
2025-04-01
Recruiting
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
NCT06904183Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
320
Guangzhou
2025-04-01
Recruiting
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
NCT06904196Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
78
Guangzhou
2025-04-01
Active, closed
Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Culture Results Are Available
NCT07514676Urolithiasis
The First Affiliated Hospital of Guangzhou Medical University
Observational
150
Guangzhou
2025-04-01
Not yet open
An Intelligent Pressure and Temperature Control Ureteral Soft Scope System for Treating Stones With Infection.
NCT06841523Ureterolithiasis, Renal Calculi
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
288
Guangzhou
2025-04-01
Not yet open
Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke
NCT06870448Acute Ischemic Stroke
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
1,614
Guangzhou
2025-04
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983Hemophilia A
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Active, closed
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486Obesity and Overweight
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
By invitation
TAF in Early/Middle Pregnancy With CHB
NCT07668934Hepatitis B Infection, Pregnant Women, Early Pregnancy
The Third Affiliated Hospital of Guangzhou Medical University
Phase 4
816
Guangzhou
2025-03-31
Recruiting
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
NCT06923345Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
80
Guangzhou
2025-03-31
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Active, closed
Anxiety in Cataract Patients Using Preoperative Music Therapy
NCT07296731Cataract, Music Therapy
Guangzhou First People's Hospital
Not applicable
60
Guangzhou
2025-03-31
Recruiting
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
NCT06868836Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
78
Guangzhou
2025-03-30
Not yet open
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
NCT06900478Hepatocarcinoma
Hua Li
Phase 2
25
Guangzhou
2025-03-30
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou
2025-03-28
Active, closed
QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer
NCT07205497Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
54
Guangzhou
2025-03-28
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
Sanofi
Phase 2
204
Guangzhou, Hangzhou, Huizhou, Jiazhuang, Linhai, Luoyang, Shanghai, Wuhan
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
NCT06898385Pancreatic Cancer
Sun Yat-sen University
Phase 1
9
Guangzhou
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Recruiting
Tubeless VATS for Mediastinal Neoplasm
NCT07065604Mediastinal Neoplasm, VATS, Tubeless, Non-intubated Anesthesia
Shuben Li
Not applicable
132
Guangzhou
2025-03-26
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
NCT07056777Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
Phase 1/2
186
Guangzhou
2025-03-25
Recruiting
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
NCT06837922Asthma
Shanghai Mabgeek Biotech.Co.Ltd
Phase 3
504
Guangzhou
2025-03-25
Not yet open
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
NCT06815705Head and Neck Squamous Cell Carcinoma, Lymphedema, Secondary, Neck Lymph Dissection, Vascularized Lymph Node Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
23
Guangzhou
2025-03-20
Recruiting
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
NCT07336979Resectable Mucosal Melanoma
Sun Yat-sen University
Phase 2
32
Guangzhou
2025-03-20
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
NCT06826313Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
12
Guangzhou
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
NCT06758544Pancreatic Cancer
Guangdong Provincial People's Hospital
Phase 1/2
18
Guangzhou
2025-03-17
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial
NCT06898216Kidney Stones
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
400
Guangzhou
2025-03-16
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Recruiting
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
NCT06587802Adrenocortical Carcinoma
Sun Yat-sen University
Phase 2
18
Guangzhou
2025-03-14
Active, closed
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
NCT06883630Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
Recruiting
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
NCT06798207Gynecological Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
NCT07412314Recurrent Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center
Not applicable
52
Guangzhou, Guanzhou
2025-03-10
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Not yet open
Clinical Features and Current Treatment of Primary Headache
NCT06883955Primary Headache
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou
2025-03-08
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an
2025-03-07
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
Fuzhou, Guangzhou, Shanghai, Chengdu
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia
NCT07571096Polycystic Ovary Syndrome (PCOS), Thrombophilia
Guangdong Women and Children Hospital
Observational
100
Guangzhou
2025-03-04
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
Recruiting
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
NCT06848400Gastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric Dysplasia
Nanfang Hospital, Southern Medical University
Not applicable
482
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Wuxi, Ganzhou, Mianyang
2025-03-03
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Not yet open
Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods
NCT06849739Inflammatory Bowel Diseases
Nanfang Hospital, Southern Medical University
Observational
60
Guangzhou
2025-03-02
Recruiting
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
NCT06851299Metastatic Triple-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
60
Guangzhou
2025-03-01
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
By invitation
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
NCT06843681Breast Carcinoma in Situ
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
54
Guangzhou
2025-03-01
Recruiting
Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
NCT07588737Postoperative Care, Rehabilitation, Artificial Intelligence (Al), Randomized Controlled Trial (RCT)
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
868
Guangzhou
2025-03-01
Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension
NCT06970509Esophageal Varices, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Not yet open
CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair
NCT06814210Mitral Regurgitation, Functional Mitral Regurgitation, Degenerative Mitral Valve Regurgitation
Xiao-dong Zhuang
Not applicable
120
Guangzhou
2025-03-01
Not yet open
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
NCT06871527Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2
44
Guangzhou
2025-03-01
Recruiting
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
NCT06854250Metastatic Prostate Cancer
Sun Yat-sen University
Phase 2
104
Guangzhou
2025-03-01
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Not yet open
Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial
NCT06825676Renal Insufficiency, Chronic, Cardiovascular Diseases (CVD)
Guangdong Provincial People's Hospital
Not applicable
1,800
Guangzhou
2025-03
Not yet open
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT06860789Chemotherapy-induced Peripheral Neuropathy (CIPN)
Akeso
Phase 1
85
Guangzhou, Shanghai
2025-02-28
Not yet open
The Effects of Glasses-Free 3D Training on Visual and Cognitive Function in Presbyopic Individuals
NCT06853691Presbyopia
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
60
Guangzhou
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Active, closed
Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)
NCT06892301Type 1 Primary Hyperoxaluria
Guangzhou Women and Children's Medical Center
Phase EARLY_PHASE1
2
Guangzhou
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379Solid Tumors
Hansoh BioMedical R&D Company
Phase 1
475
Guangzhou
2025-02-26
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
NCT06793956Extranodal Natural Killer/T Cell Lymphoma
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-02-21
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Active, closed
Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.
NCT06854510Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2/3
196
Guangzhou
2025-02-21
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Recruiting
Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
NCT06861114Hepatocellular Carcinoma (HCC)
Zhujiang Hospital
Observational
38
Guangzhou
2025-02-20
Recruiting
Modified Tumor-free Techniques Operation to Cervical Cancer
NCT06836869Cervical Cancer Stage IB2
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Not yet open
Observation on Administration of Propofol at Different Titration Endpoints
NCT06685198Anesthesia, General, Hemodynamics
SanQing Jin
Not applicable
258
Guangzhou
2025-02-20
Recruiting
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06676631Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis
Guangdong Provincial People's Hospital
Phase 1
18
Guangzhou
2025-02-19
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
NCT06703177Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
876
Guangzhou
2025-02-18
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
NCT06926790Lung Cancer - Non Small Cell
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
69
Guangzhou
2025-02-17
Not yet open
A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
NCT06825949Breast Cancers
Guangdong Provincial People's Hospital
Not applicable
55
Guangzhou
2025-02-15
Recruiting
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
NCT06831357Nasopharyngeal Cancinoma (NPC), Distant Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2025-02-15
Recruiting
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
NCT06819826IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.
Phase 3
360
Guangzhou
2025-02-14
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 3
324
Beijing, Guangzhou, Wuhan, Shanghai Shi
2025-02-12
Rows per page Showing 1301–1400 of 3318
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=14

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.